News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Pacira Pharmaceuticals, Inc. Reports 2012 Financial Results
March 7, 2013
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated 2012 financial results and provided updates on the commercial launch of EXPAREL®(bupivacaine liposome injectable suspension) for postsurgical pain in the United States.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Pacira Biosciences
MORE ON THIS TOPIC
Manufacturing
Sun Pharma recalls cancer drug after finding glass particles in some vials
May 15, 2026
·
2 min read
·
Nick Paul Taylor
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
May 15, 2026
·
3 min read
·
Annalee Armstrong
Series B
CREATE jumps into CAR T competition with $122M series B
May 15, 2026
·
2 min read
·
Tristan Manalac
Funding
Degron adds $40M to series A, supporting immunology plans for molecular glue platform
May 14, 2026
·
2 min read
·
Tristan Manalac
